# Study of Antibiotic Utilization Measures and Control of ESBLs in China

> **NCT00488813** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 300 (—)

## Conditions studied

- ICU Patient

## Interventions

- **DRUG:** Third generation cephalosporins

## Key facts

- **NCT ID:** NCT00488813
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 300 (—)
- **Last updated:** 2009-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488813, "Study of Antibiotic Utilization Measures and Control of ESBLs in China". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00488813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*